Press releasePRNewswire
PAVmed
PAVM · NASDAQ
$2.23−$0.02 (−0.89%)TodayMarket closed ·
Prev close $2.25
Latest news
- News
PAVmed Q2 2026 Earnings Call: Complete Transcript
- Press releasePRNewswire
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
- Press releasePRNewswire
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test
- Press releasePRNewswire
Lucid Diagnostics to Participate in Upcoming Investor Conferences
- Press releasePRNewswire
PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026
- Press releasePRNewswire
Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026
- News
PAVmed Q1 2026 Earnings Call Transcript
- Press releasePRNewswire
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
- News
Earnings Scheduled For May 15, 2026
- Press releasePRNewswire
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
PAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026
- Press releasePRNewswire
Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026
- Press releasePRNewswire
Lucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common Stock
- Press releasePRNewswire
Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock
- Press releasePRNewswire
Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
- Press releasePRNewswire
PAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device Portfolio
- Press releasePRNewswire
PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
- News
Earnings Scheduled For March 30, 2026
- Press releasePRNewswire
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
- Press releasePRNewswire
PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026
- Press releasePRNewswire
Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
- Press releasePRNewswire
PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
- NewsDylan Berman
What's Going On With PAVmed Shares Thursday?
- NewsAvi Kapoor
Nasdaq Edges Lower; Johnson & Johnson Earnings Top Estimates
- NewsAkanksha Bakshi
Why Is PAVmed Stock Skyrocketing Wednesday?
- NewsAvi Kapoor
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results
- Press releasePRNewswire
Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
- Press releasePRNewswire
PAVmed Announces Reverse Stock Split
- Press releasePRNewswire
Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
- Press releasePRNewswire
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
- News
Earnings Scheduled For November 13, 2025
- Press releasePRNewswire
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
- News
Earnings Scheduled For August 14, 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.